Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:DRUG NASDAQ:IZTC NASDAQ:TSVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$5.14+9.0%$4.07$2.25▼$7.53$493.62M2.171.82 million shs3.15 million shsDRUGBright Minds Biosciences$45.12+4.3%$33.92$0.94▼$79.02$317.12M-6.1451,066 shs393,026 shsIZTCInvizyne Technologies$10.19+5.1%$9.82$8.50▼$23.00$63.68MN/A37,647 shs6,170 shsTSVT2seventy bio$5.00$5.00$2.29▼$5.30$266.15M1.04650,169 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways+4.20%-0.21%+2.39%+3.97%-34.81%DRUGBright Minds Biosciences+11.52%-0.21%+21.99%+55.59%+3,888.02%IZTCInvizyne Technologies0.00%+4.19%-3.72%-28.15%+969,999,900.00%TSVT2seventy bio0.00%0.00%0.00%0.00%+12.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$5.14+9.0%$4.07$2.25▼$7.53$493.62M2.171.82 million shs3.15 million shsDRUGBright Minds Biosciences$45.12+4.3%$33.92$0.94▼$79.02$317.12M-6.1451,066 shs393,026 shsIZTCInvizyne Technologies$10.19+5.1%$9.82$8.50▼$23.00$63.68MN/A37,647 shs6,170 shsTSVT2seventy bio$5.00$5.00$2.29▼$5.30$266.15M1.04650,169 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways+4.20%-0.21%+2.39%+3.97%-34.81%DRUGBright Minds Biosciences+11.52%-0.21%+21.99%+55.59%+3,888.02%IZTCInvizyne Technologies0.00%+4.19%-3.72%-28.15%+969,999,900.00%TSVT2seventy bio0.00%0.00%0.00%0.00%+12.87%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$1.69 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$5.32 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ATSVT2seventy bio$48.37M5.50N/AN/A$5.04 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ATSVT2seventy bio-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%N/ALatest IZTC, CMPS, TSVT, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82DRUGBright Minds BiosciencesN/A86.6486.64IZTCInvizyne TechnologiesN/AN/AN/ATSVT2seventy bioN/A4.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%DRUGBright Minds Biosciences40.52%IZTCInvizyne TechnologiesN/ATSVT2seventy bio93.90%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%DRUGBright Minds Biosciences42.66%IZTCInvizyne TechnologiesN/ATSVT2seventy bio7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/ATSVT2seventy bio44053.23 million47.87 millionOptionableIZTC, CMPS, TSVT, and DRUG HeadlinesRecent News About These Companies2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.com2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.comJessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockMarch 20, 2025 | insidertrades.com2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's WhyMarch 17, 2025 | zacks.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14, 2025 | insidertrades.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12, 2025 | prnewswire.comShareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 11, 2025 | businesswire.com2seventy bio accepts Bristol Myers’ takeover bidMarch 11, 2025 | thepharmaletter.comTBiotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition NewsMarch 11, 2025 | investorideas.comITSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to ShareholdersMarch 11, 2025 | tmcnet.com2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashMarch 11, 2025 | markets.businessinsider.comTSVT Up on Acquisition Agreement With BMY for $286 MillionMarch 11, 2025 | zacks.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.March 11, 2025 | prnewswire.comBristol Myers buys out cell therapy partner 2seventy bioMarch 11, 2025 | endpts.comE2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbMarch 10, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, CMPS, TSVT, and DRUG Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$5.14 +0.43 (+9.02%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Bright Minds Biosciences NASDAQ:DRUG$45.12 +1.85 (+4.28%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Invizyne Technologies NASDAQ:IZTC$10.18 +0.49 (+5.09%) As of 09/3/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.2seventy bio NASDAQ:TSVT2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
